Advertisement

Bullous Pemphigoid

  • Megan H. Noe
  • Janet A. FairleyEmail author
Chapter

Abstract

Bullous pemphigoid is the most common cutaneous autoimmune blistering diseases with an estimated incidence in the United States of 24 cases per million person-years. It is a chronic disease of the elderly that can cause significant morbidity secondary to pruritus and open wounds. High potency topical corticosteroids are effective for patients with limited disease and in treating disease flares. Oral corticosteroids are the main stay of early treatment for more extensive disease because of their fast onset of action, but should not be used for long-term management at high doses because of the significant risk of potentially serious side effects. Steroid-sparing agents such as azathioprine, mycophenolate mofetil and methotrexate have shown to be effective in decreasing the dose of systemic corticosteroids required. For more recalcitrant cases, IVIG and rituximab can also be considered. The choice of an appropriate treatment must also balance the risks of systemic immunosuppression in this elderly population with other medical comorbidities.

Keywords

Bullous pemphigoid Autoimmune blistering disease Treatment Topical steroids Systemic steroids Tetracycline Minocycline Niacinamide Dapsone Methotrexate Azathioprine Mycophenolate mofetil Cyclosporine Plasmapheresis IVIG Rituximab Cyclophosphamide Omalizumab 

Abbreviations

ABD

Autoimmune bullous disease

BP

Bullous pemphigoid

BSA

Body surface area

IF

Immunofluorescence

IVIG

Intravenous immunoglobulin

mg/m2

milligrams per square meter

References

  1. 1.
    Bernard P, Borradori L. Pemphigoid group. In: Bolognia J, Jorizzo J, Rapini R, editors. Dermatology (Basel, Switzerland). 3rd ed. Philadelphia: Elsevier; 2012. p. 475–90.Google Scholar
  2. 2.
    Bernard P, Vaillant L, Labeille B, Bedane C, Arbeille B, Denoeux JP, et al. Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous Diseases French Study Group. Arch Dermatol. 1995;131(1):48–52.CrossRefPubMedGoogle Scholar
  3. 3.
    Zillikens D, Wever S, Roth A, Weidenthaler-Barth B, Hashimoto T, Brocker EB. Incidence of autoimmune subepidermal blistering dermatoses in a region of central Germany. Arch Dermatol. 1995;131(8):957–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Joly P, Baricault S, Sparsa A, Bernard P, Bedane C, Duvert-Lehembre S, et al. Incidence and mortality of bullous pemphigoid in France. J Invest Dermatol. 2012;132(8):1998–2004.CrossRefPubMedGoogle Scholar
  5. 5.
    Langan SM, Smeeth L, Hubbard R, Fleming KM, Smith CJ, West J. Bullous pemphigoid and pemphigus vulgaris--incidence and mortality in the UK: population based cohort study. BMJ (Clin Res Ed). 2008;337:a180.CrossRefGoogle Scholar
  6. 6.
    Bertram F, Brocker EB, Zillikens D, Schmidt E. Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany. J Dtsch Dermatol Ges. 2009;7(5):434–40.PubMedGoogle Scholar
  7. 7.
    Brick KE, Weaver CH, Lohse CM, Pittelkow MR, Lehman JS, Camilleri MJ, et al. Incidence of bullous pemphigoid and mortality of patients with bullous pemphigoid in Olmsted County, Minnesota, 1960 through 2009. J Am Acad Dermatol. 2014;71(1):92–9.PubMedCentralCrossRefPubMedGoogle Scholar
  8. 8.
    Jung M, Kippes W, Messer G, Zillikens D, Rzany B. Increased risk of bullous pemphigoid in male and very old patients: a population-based study on incidence. J Am Acad Dermatol. 1999;41(2 Pt 1):266–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Parker SR, Dyson S, Brisman S, Pennie M, Swerlick RA, Khan R, et al. Mortality of bullous pemphigoid: an evaluation of 223 patients and comparison with the mortality in the general population in the United States. J Am Acad Dermatol. 2008;59(4):582–8.CrossRefPubMedGoogle Scholar
  10. 10.
    Colbert RL, Allen DM, Eastwood D, Fairley JA. Mortality rate of bullous pemphigoid in a US medical center. J Invest Dermatol. 2004;122(5):1091–5.CrossRefPubMedGoogle Scholar
  11. 11.
    Kirtschig G, Middleton P, Bennett C, Murrell DF, Wojnarowska F, Khumalo NP. Interventions for bullous pemphigoid. Cochrane Database Syst Rev. 2010(10):CD002292.Google Scholar
  12. 12.
    Joly P, Roujeau JC, Benichou J, Picard C, Dreno B, Delaporte E, et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med. 2002;346(5):321–7.CrossRefPubMedGoogle Scholar
  13. 13.
    Joly P, Roujeau JC, Benichou J, Delaporte E, D’Incan M, Dreno B, et al. A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study. J Invest Dermatol. 2009;129(7):1681–7.CrossRefPubMedGoogle Scholar
  14. 14.
    Ingen-Housz-Oro S, Valeyrie-Allanore L, Ortonne N, Roujeau JC, Wolkenstein P, Chosidow O. Management of bullous pemphigoid with topical steroids in the clinical practice of a single center: outcome at 6 and 12 months. Dermatol (Basel Switzerland). 2011;222(2):176–9.CrossRefGoogle Scholar
  15. 15.
    Westerhof W. Treatment of bullous pemphigoid with topical clobetasol propionate. J Am Acad Dermatol. 1989;20(3):458–61.CrossRefPubMedGoogle Scholar
  16. 16.
    Chu J, Bradley M, Marinkovich MP. Topical tacrolimus is a useful adjunctive therapy for bullous pemphigoid. Arch Dermatol. 2003;139(6):813–5.CrossRefPubMedGoogle Scholar
  17. 17.
    Morel P, Guillaume JC. Treatment of bullous pemphigoid with prednisolone only: 0.75 mg/kg/day versus 1.25 mg/kg/day. A multicenter randomized study. Ann Dermatol Venereol. 1984;111(10):925–8.PubMedGoogle Scholar
  18. 18.
    Dreno B, Sassolas B, Lacour P, Montpoint S, Lota I, Giordano F, et al. Methylprednisolone versus prednisolone methylsulfobenzoate in pemphigoid: a comparative multicenter study. Ann Dermatol Venereol. 1993;120(8):518–21.PubMedGoogle Scholar
  19. 19.
    Chosidow O, Saada V, Diquet B, Roujeau JC, Revuz J. Correlation between the pretreatment number of blisters and the time to control bullous pemphigoid with prednisone 1 mg/kg/day. Br J Dermatol. 1992;127(2):185–6.CrossRefPubMedGoogle Scholar
  20. 20.
    Loo WJ, Kirtschig G, Wojnarowska F. Minocycline as a therapeutic option in bullous pemphigoid. Clin Exp Dermatol. 2001;26(5):376–9.CrossRefPubMedGoogle Scholar
  21. 21.
    Thornfeldt CR, Menkes AW. Bullous pemphigoid controlled by tetracycline. J Am Acad Dermatol. 1987;16(2 Pt 1):305–10.CrossRefPubMedGoogle Scholar
  22. 22.
    Altomare G, Capella GL, Fracchiolla C, Frigerio E. Treatment of bullous pemphigoid with erythromycin: a reappraisal. Eur J Dermatol. 1999;9(7):583–5.PubMedGoogle Scholar
  23. 23.
    Fivenson DP, Breneman DL, Rosen GB, Hersh CS, Cardone S, Mutasim D. Nicotinamide and tetracycline therapy of bullous pemphigoid. Arch Dermatol. 1994;130(6):753–8.CrossRefPubMedGoogle Scholar
  24. 24.
    Berk MA, Lorincz AL. The treatment of bullous pemphigoid with tetracycline and niacinamide. A preliminary report. Arch Dermatol. 1986;122(6):670–4.CrossRefPubMedGoogle Scholar
  25. 25.
    Kolbach DN, Remme JJ, Bos WH, Jonkman MF, De Jong MC, Pas HH, et al. Bullous pemphigoid successfully controlled by tetracycline and nicotinamide. Br J Dermatol. 1995;133(1):88–90.CrossRefPubMedGoogle Scholar
  26. 26.
    Shiohara J, Yoshida K, Hasegawa J, Uhara H, Takata M, Saida T, et al. Tetracycline and niacinamide control bullous pemphigoid but not pemphigus foliaceus when these conditions coexist. J Dermatol. 2010;37(7):657–61.CrossRefPubMedGoogle Scholar
  27. 27.
    Honl BA, Elston DM. Autoimmune bullous eruption localized to a breast reconstruction site: response to niacinamide. Cutis. 1998;62(2):85–6.PubMedGoogle Scholar
  28. 28.
    Venning VA, Millard PR, Wojnarowska F. Dapsone as first line therapy for bullous pemphigoid. Br J Dermatol. 1989;120(1):83–92.CrossRefPubMedGoogle Scholar
  29. 29.
    Bouscarat F, Chosidow O, Picard-Dahan C, Sakiz V, Crickx B, Prost C, et al. Treatment of bullous pemphigoid with dapsone: retrospective study of thirty-six cases. J Am Acad Dermatol. 1996;34(4):683–4.CrossRefPubMedGoogle Scholar
  30. 30.
    Jeffes 3rd EW, Ahmed AR. Adjuvant therapy of bullous pemphigoid with dapsone. Clin Exp Dermatol. 1989;14(2):132–6.CrossRefPubMedGoogle Scholar
  31. 31.
    Guillaume JC, Vaillant L, Bernard P, Picard C, Prost C, Labeille B, et al. Controlled trial of azathioprine and plasma exchange in addition to prednisolone in the treatment of bullous pemphigoid. Arch Dermatol. 1993;129(1):49–53.CrossRefPubMedGoogle Scholar
  32. 32.
    Burton JL, Harman RR, Peachey RD, Warin RP. Azathioprine plus prednisone in treatment of pemphigoid. Br Med J. 1978;2(6146):1190–1.PubMedCentralCrossRefPubMedGoogle Scholar
  33. 33.
    Beissert S, Werfel T, Frieling U, Bohm M, Sticherling M, Stadler R, et al. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid. Arch Dermatol. 2007;143(12):1536–42.CrossRefPubMedGoogle Scholar
  34. 34.
    Ahmed AR, Maize JC, Provost TT. Bullous pemphigoid. Clinical and immunologic follow-up after successful therapy. Arch Dermatol. 1977;113(8):1043–6.CrossRefPubMedGoogle Scholar
  35. 35.
    Greaves MW, Burton JL, Marks J, Dawber RP. Azathioprine in treatment of bullous pemphigoid. Br Med J. 1971;1(5741):144–5.PubMedCentralCrossRefPubMedGoogle Scholar
  36. 36.
    Burton JL, Greaves MW. Azathioprine for pemphigus and pemphigoid – a 4 year follow-up. Br J Dermatol. 1974;91(1):103–9.CrossRefPubMedGoogle Scholar
  37. 37.
    van Dijk TJ, van Velde JL. Treatment of pemphigus and pemphigoid with azathioprine. Dermatologica. 1973;147(3):179–85.CrossRefPubMedGoogle Scholar
  38. 38.
    Schram ME, Borgonjen RJ, Bik CM, van der Schroeff JG, van Everdingen JJ, Spuls PI. Off-label use of azathioprine in dermatology: a systematic review. Arch Dermatol. 2011;147(4):474–88.CrossRefPubMedGoogle Scholar
  39. 39.
    Gunay U, Gunduz K, Ermertcan AT, Kandiloglu AR. Coexistence of psoriasis and bullous pemphigoid: remission with low-dose methotrexate. Cutan Ocul Toxicol. 2013;32(2):168–9.CrossRefPubMedGoogle Scholar
  40. 40.
    Bara C, Maillard H, Briand N, Celerier P. Methotrexate for bullous pemphigoid: preliminary study. Arch Dermatol. 2003;139(11):1506–7.CrossRefPubMedGoogle Scholar
  41. 41.
    Dereure O, Bessis D, Guillot B, Guilhou JJ. Treatment of bullous pemphigoid by low-dose methotrexate associated with short-term potent topical steroids: an open prospective study of 18 cases. Arch Dermatol. 2002;138(9):1255–6.CrossRefPubMedGoogle Scholar
  42. 42.
    Heilborn JD, Stahle-Backdahl M, Albertioni F, Vassilaki I, Peterson C, Stephansson E. Low-dose oral pulse methotrexate as monotherapy in elderly patients with bullous pemphigoid. J Am Acad Dermatol. 1999;40(5 Pt 1):741–9.CrossRefPubMedGoogle Scholar
  43. 43.
    Bohm I, Bauer R. Treatment of bullous pemphigoid with low-dose methotrexate. Der Hautarzt Zeitschrift fur Dermatologie Venerologie und verwandte Gebiete. 1997;48(12):910–4.CrossRefGoogle Scholar
  44. 44.
    Paul MA, Jorizzo JL, Fleischer Jr AB, White WL. Low-dose methotrexate treatment in elderly patients with bullous pemphigoid. J Am Acad Dermatol. 1994;31(4):620–5.CrossRefPubMedGoogle Scholar
  45. 45.
    Kjellman P, Eriksson H, Berg P. A retrospective analysis of patients with bullous pemphigoid treated with methotrexate. Arch Dermatol. 2008;144(5):612–6.CrossRefPubMedGoogle Scholar
  46. 46.
    Bohm M, Beissert S, Schwarz T, Metze D, Luger T. Bullous pemphigoid treated with mycophenolate mofetil. Lancet. 1997;349(9051):541.CrossRefPubMedGoogle Scholar
  47. 47.
    Nousari HC, Griffin WA, Anhalt GJ. Successful therapy for bullous pemphigoid with mycophenolate mofetil. J Am Acad Dermatol. 1998;39(3):497–8.CrossRefPubMedGoogle Scholar
  48. 48.
    Grundmann-Kollmann M, Korting HC, Behrens S, Kaskel P, Leiter U, Krahn G, et al. Mycophenolate mofetil: a new therapeutic option in the treatment of blistering autoimmune diseases. J Am Acad Dermatol. 1999;40(6 Pt 1):957–60.CrossRefPubMedGoogle Scholar
  49. 49.
    Barthelemy H, Thivolet J, Cambazard F, Bendelac A, Mauduit G, Granier F, et al. Cyclosporin in the treatment of bullous pemphigoid: preliminary study. Ann Dermatol Venereol. 1986;113(4):309–13.PubMedGoogle Scholar
  50. 50.
    Thivolet J, Barthelemy H, Rigot-Muller G, Bendelac A. Effects of cyclosporin on bullous pemphigoid and pemphigus. Lancet. 1985;1(8424):334–5.CrossRefPubMedGoogle Scholar
  51. 51.
    Roujeau JC, Revuz J, Touraine R, Joneau-Fabre M, Mannoni P. Cortico-resistant bullous pemphigoid. Favorable results with plasmapheresis. Nouv Presse Med. 1979;8(41):3362.PubMedGoogle Scholar
  52. 52.
    Guillaume JC, Roujeau JC, Touzet C, Revuz J, Touraine R. [Treatment of bullous pemphigoid by plasma exchange and prednisolone]. Presse Med (Paris France: 1983). 1985;14(20):1139–42.Google Scholar
  53. 53.
    Roujeau JC, Guillaume JC, Morel P, Crickx B, Dalle E, Doutre MS, et al. Plasma exchange in bullous pemphigoid. Lancet. 1984;2(8401):486–8.CrossRefPubMedGoogle Scholar
  54. 54.
    Yamada H, Yaguchi H, Takamori K, Ogawa H. Plasmapheresis for the treatment of pemphigus vulgaris and bullous pemphigoid. Therap A. 1997;1(2):178–82.CrossRefGoogle Scholar
  55. 55.
    Egan CA, Meadows KP, Zone JJ. Plasmapheresis as a steroid saving procedure in bullous pemphigoid. Int J Dermatol. 2000;39(3):230–5.CrossRefPubMedGoogle Scholar
  56. 56.
    Mazzi G, Raineri A, Zanolli FA, Da Ponte C, De Roia D, Santarossa L, et al. Plasmapheresis therapy in pemphigus vulgaris and bullous pemphigoid. Transfus A Sci. 2003;28(1):13–8.CrossRefGoogle Scholar
  57. 57.
    Chang B, Tholpady A, Huang RS, Nedelcu E, Bai Y. Clinical and serological responses following plasmapheresis in bullous pemphigoid: two case reports and a review of the literature. Blood Transfus. 2014;12(2):269–75.PubMedCentralPubMedGoogle Scholar
  58. 58.
    Kitabata Y, Sakurane M, Orita H, Kamimura M, Siizaki K, Narukawa N, et al. Double filtration plasmapheresis for the treatment of bullous pemphigoid: a three case report. Ther A. 2001;5(6):484–90.Google Scholar
  59. 59.
    Lee MW, Lee WS, Choi JH, Sung KJ, Moon KC, Koh JK. A case of severe bullous pemphigoid treated with plasmapheresis. J Dermatolog Treat. 2001;12(1):59–60.CrossRefPubMedGoogle Scholar
  60. 60.
    Konstadt JW, Remlinger K, Schild J, Aronson I, Bennin B, Solomon L. Refractory bullous pemphigoid leading to respiratory arrest and successfully treated with plasmapheresis. Arch Dermatol. 1990;126(9):1241–2.CrossRefPubMedGoogle Scholar
  61. 61.
    Guillot B, Donadio D, Guilhou JJ, Meynadier J. Long term plasma exchange therapy in bullous pemphigoid. Acta Derm Venereol. 1986;66(1):73–5.PubMedGoogle Scholar
  62. 62.
    Muller PA, Brocker EB, Klinker E, Stoevesandt J, Benoit S. Adjuvant treatment of recalcitrant bullous pemphigoid with immunoadsorption. Dermatol (Basel Switzerland). 2012;224(3):224–7.CrossRefGoogle Scholar
  63. 63.
    Godard W, Roujeau JC, Guillot B, Andre C, Rifle G. Bullous pemphigoid and intravenous gammaglobulin. Ann Int Med. 1985;103(6 (Pt 1)):964–5.PubMedGoogle Scholar
  64. 64.
    Ahmed AR. Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment. J Am Acad Dermatol. 2001;45(6):825–35.CrossRefPubMedGoogle Scholar
  65. 65.
    Sami N, Ali S, Bhol KC, Ahmed AR. Influence of intravenous immunoglobulin therapy on autoantibody titres to BP Ag1 and BP Ag2 in patients with bullous pemphigoid. J Eur Acad Dermatol Venereo. 2003;17(6):641–5.CrossRefGoogle Scholar
  66. 66.
    Lourari S, Herve C, Doffoel-Hantz V, Meyer N, Bulai-Livideanu C, Viraben R, et al. Bullous and mucous membrane pemphigoid show a mixed response to rituximab: experience in seven patients. J Eur Acad Dermatol Venereo. 2011;25(10):1238–40.CrossRefGoogle Scholar
  67. 67.
    Hall 3rd RP, Streilein RD, Hannah DL, McNair PD, Fairley JA, Ronaghy A, et al. Association of serum B-cell activating factor level and proportion of memory and transitional B cells with clinical response after rituximab treatment of bullous pemphigoid patients. J Invest Dermatol. 2013;133(12):2786–8.CrossRefPubMedGoogle Scholar
  68. 68.
    Saouli Z, Papadopoulos A, Kaiafa G, Girtovitis F, Kontoninas Z. A new approach on bullous pemphigoid therapy. Ann Oncol. 2008;19(4):825–6.CrossRefPubMedGoogle Scholar
  69. 69.
    Reguiai Z, Tchen T, Perceau G, Bernard P. Efficacy of rituximab in a case of refractory bullous pemphigoid. Ann Dermatol Venereol. 2009;136(5):431–4.CrossRefPubMedGoogle Scholar
  70. 70.
    Saraceno R, Citarella L, Spallone G, Chimenti S. A biological approach in a patient with psoriasis and bullous pemphigoid associated with losartan therapy. Clin Exp Dermatol. 2008;33(2):154–5.CrossRefPubMedGoogle Scholar
  71. 71.
    Kasperkiewicz M, Shimanovich I, Ludwig RJ, Rose C, Zillikens D, Schmidt E. Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients. J Am Acad Dermatol. 2011;65(3):552–8.CrossRefPubMedGoogle Scholar
  72. 72.
    Wang TS, Tsai TF. Remission of bullous pemphigoid after rituximab treatment in a psoriasis patient on regular low-dose methotrexate. Acta Derm Venereol. 2014;94(1):108–9.CrossRefPubMedGoogle Scholar
  73. 73.
    Schmidt E, Seitz CS, Benoit S, Brocker EB, Goebeler M. Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. Br J Dermatol. 2007;156(2):352–6.CrossRefPubMedGoogle Scholar
  74. 74.
    Taieb A, Klene C, Maleville J. Immediate treatment of bullous pemphigus with a corticosteroid-cyclophosphamide combination. Ann Dermatol Venereol. 1986;113(12):1223–9.PubMedGoogle Scholar
  75. 75.
    Gual A, Iranzo P, Mascaro Jr JM. Treatment of bullous pemphigoid with low-dose oral cyclophosphamide: a case series of 20 patients. J Eur Acad Dermatol Venereo. 2014;28(6):814–8.CrossRefGoogle Scholar
  76. 76.
    Dawe RS, Naidoo DK, Ferguson J. Severe bullous pemphigoid responsive to pulsed intravenous dexamethasone and oral cyclophosphamide. Br J Dermatol. 1997;137(5):826–7.CrossRefPubMedGoogle Scholar
  77. 77.
    Yu KK, Crew AB, Messingham KA, Fairley JA, Woodley DT. Omalizumab therapy for bullous pemphigoid. J Am Acad Dermatol. 2014;71(3):468–74.CrossRefPubMedGoogle Scholar
  78. 78.
    Dufour C, Souillet AL, Chaneliere C, Jouen F, Bodemer C, Jullien D, et al. Successful management of severe infant bullous pemphigoid with omalizumab. Br J Dermatol. 2012;166(5):1140–2.CrossRefPubMedGoogle Scholar
  79. 79.
    Yalcin AD, Genc GE, Celik B, Gumuslu S. Anti-IgE monoclonal antibody (omalizumab) is effective in treating bullous pemphigoid and its effects on soluble CD200. Clin Lab. 2014;60(3):523–4.PubMedGoogle Scholar
  80. 80.
    Murrell DF, Daniel BS, Joly P, Borradori L, Amagai M, Hashimoto T, et al. Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts. J Am Acad Dermatol. 2012;66(3):479–85.CrossRefPubMedGoogle Scholar
  81. 81.
    Saag KG. Bone safety of low-dose glucocorticoids in rheumatic diseases. Ann N Y Acad Sci. 2014;1318:55–64.Google Scholar
  82. 82.
    Lehman JS, Kalaaji AN. Role of primary prophylaxis for pneumocystis pneumonia in patients treated with systemic corticosteroids or other immunosuppressive agents for immune-mediated dermatologic conditions. J Am Acad Dermatol. 2010;63(5):815–23.CrossRefPubMedGoogle Scholar
  83. 83.
    Brennan JG, Montgomery H. Pemphigus and other bullous dermatoses: correlation of clinical and pathologic findings. J Invest Dermatol. 1953;21(6):349–61; discussion 61–3.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Department of DermatologyThe University of IowaIowa CityUSA

Personalised recommendations